A new partnership between two powerhouses in the pharmaceutical industry promises substantial advancements in drug discovery and development. Novartis, one of the largest pharmaceutical companies globally, will pay Schrödinger $150 million upfront to utilize its advanced computing tools and
The field of regenerative medicine has seen remarkable advancements over the past few decades, with stem cell therapies emerging as a promising frontier. These therapies hold the potential to revolutionize the treatment of a wide array of diseases and conditions by harnessing the body's own
The University of Texas MD Anderson Cancer Center has unveiled its ambitious new initiative, the Institute for Cell Therapy Discovery & Innovation, fueled by an impressive initial funding of over $80 million. This pioneering institute aims to revolutionize the realms of immunology and cell
The recent approval of Aucatzyl by the FDA marks a significant advancement in the treatment landscape for patients with B-cell precursor acute lymphoblastic leukemia, especially those whose disease has progressed following initial chemotherapy treatments. Developed by U.K.-based Autolus
South Korea's pharmaceutical and biotech industry is witnessing a fascinating shift as Contract Development and Manufacturing Organizations (CDMOs) and biosimilar developers are experiencing robust growth, while traditional pharmaceutical companies lag. At the forefront of this transition is
The victory of Donald Trump in the U.S. presidential election has sparked widespread speculation about the potential changes within federal health agencies, particularly the Food and Drug Administration (FDA) and the Federal Trade Commission (FTC). Trump's past and potential future choices for
Rallybio, a small biotech firm, is on a mission to develop treatments for rare diseases, with a particular focus on fetal and neonatal alloimmune thrombocytopenia (FNAIT). This rare but potentially fatal disease results from platelet incompatibility between pregnant mothers and their unborn
Innovent Biologics Inc. (1801.HK), a significant player in the Chinese biopharmaceutical sector, recently faced harsh backlash from investors due to a misstep in its strategy. The company aimed to strengthen its executives' dedication to its international unit, Fortvita, by selling a stake to
Naobios and Sumagen Canada Inc., a subsidiary of CreoSG Co., Ltd, have achieved a critical milestone in the development of Sumagen’s HIV-1 vaccine candidate, SAV001. This genetically modified, whole-killed HIV vaccine has shown both tolerance and safety in phase I trials, marking a significant step
Pluri Inc., a forward-thinking biotechnology firm, has recently announced a groundbreaking collaborative project with Bar-Ilan University’s Research and Development Company (BIRAD). This innovative endeavor aims to develop cutting-edge allogeneic cell therapies specifically targeting solid tumors, a
